The global cell therapy human raw materials market was estimated at USD 3.62 billion in 2025 and is projected to reach about USD 18.94 billion by 2035, growing at a 16.3% CAGR from 2026 to 2035. Growth is driven by CAR-T, NK cell and stem cell therapy development, GMP demand for human-derived and recombinant human materials, expanding production capacity, and improvements in raw material purity, characterization and traceability.
Market Highlights
North America held about 44% of the market in 2025.
Asia Pacific is expected to post the highest regional CAGR at 20.1%.
Human serum albumin held about 31% of product type share in 2025; human platelet lysate grows fastest at 21.4% CAGR.
CAR-T held the largest application share at about 38% in 2025; NK cell therapy grows fastest at 24.7% CAGR.
Recombinant human-derived materials held 57% of source share in 2025.
Growth Factors
Pipeline expansion: The cell therapy clinical pipeline, including CAR-T, TIL, NK, MSC and iPSC programs, is driving demand for GMP-grade human raw materials, with over 2,100 active cell and gene therapy trials at end-2024.
Regulatory pressure: Global GMP and ATMP rules require strict identity, purity, potency and safety controls, and regulators are moving away from animal-derived components, boosting demand for recombinant human alternatives.
Major Advances
Recombinant human albumin is increasingly replacing plasma-derived albumin for supply security and batch consistency.
Human platelet lysate is replacing fetal bovine serum in ex vivo expansion of MSCs, T cells and NK cells.
GMP-grade recombinant human cytokines such as IL-2, IL-7, IL-15 and IL-21 support better-defined manufacturing.
Recombinant human fibronectin fragments improve viral vector transduction in CAR-T manufacturing.
Category Insights
Product Type
Human serum albumin leads due to its roles in culture media, cryopreservation and final formulations. Human platelet lysate is the fastest-growing product segment.
Application
CAR-T dominates, reflecting its raw-material-intensive manufacturing; NK cell therapy is the fastest-growing application.
End-User and Source
Biopharmaceutical and biotechnology companies hold about 52% share; CDMOs are the fastest-growing end-user. Recombinant human-derived materials lead and are projected to reach about 68% share by 2030.
Regional Analysis
North America is estimated at USD 1.59 billion in 2025 and is projected to reach about USD 7.13 billion by 2035. Europe is the second-largest region, supported by its ATMP framework. Asia Pacific is the fastest-growing region, led by Japan's regenerative medicine framework and China's expanding CAR-T and supplier base. The Middle East, Africa and Latin America are emerging markets.
Key Developments
April 2021: Albumedix announced a USD 35 million expansion of its recombinant albumin GMP plant in Nottingham, UK.
January 2025: Merck KGaA (MilliporeSigma) expanded its UltraGROWTH HPL line with two pathogen-inactivated grades.
March 2025: Takara Bio signed a strategic supply alliance with a North American CDMO to secure GMP-grade RetroNectin supply.
Meet the team
This report was prepared by our expert analysts with deep industry knowledge and hands-on research experience.
VJ
Veena Jagtap
Author · Healthcare Research Manager
A results-driven Healthcare Research Manager at Custom Market Insights, specializing in healthcare market intelligence, industry analysis, competitive benchmarking, and strategic market assessments. Experienced in managing end-to-end healthcare research projects, analyzing industry trends, evaluating competitive landscapes, and identifying emerging market opportunities across pharmaceuticals, biotechnology, medical devices, healthcare services, and life sciences.
Skilled in leading research initiatives, developing customized research methodologies, and transforming complex market data into actionable business insights. With a strong analytical mindset, strategic perspective, and commitment to research excellence, I focus on delivering accurate, data-driven intelligence that empowers clients to make informed business decisions, strengthen market positioning, and achieve sustainable growth in the evolving global healthcare industry.
Table of Contents
Explore the chapters covered in the full report.
Chapter 1. Report Introduction
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 USP & Key Offerings
1.2 Key Benefits For Stakeholders
1.3 Target Audience
1.4 Report Scope
Chapter 2. Market Overview
2.1 Market Definition & Scope
2.2 Key Market Takeaways
2.3 Market Snapshot
Chapter 3. Market Dynamics (DRO)
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Market Trends
Chapter 4. Cell Therapy Human Raw Materials Market - By product type
4.1 human serum albumin
4.2 human platelet lysate
4.3 recombinant cytokines
4.4 fibronectin fragments
Chapter 5. Cell Therapy Human Raw Materials Market - By application
5.1 CAR-T
5.2 NK cell therapy
5.3 stem cell therapy
Chapter 6. Cell Therapy Human Raw Materials Market - By source
6.1 recombinant human-derived
6.2 plasma-derived
Chapter 7. Cell Therapy Human Raw Materials Market - By end-user
7.1 biopharmaceutical companies
7.2 CDMOs
7.3 academic/research
Chapter 8. Cell Therapy Human Raw Materials Market - Regional Analysis
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Middle East & Africa
8.5 Latin America
Chapter 9. Competitive Landscape
9.1 Market Share Analysis
9.2 Company Benchmarking
9.3 Strategic Developments
Chapter 10. Company Profiles
10.1 Thermo Fisher Scientific
10.2 Merck KGaA (MilliporeSigma)
10.3 Sartorius AG
10.4 Albumedix
10.5 Takara Bio
10.6 CellGenix
10.7 Macopharma
10.8 Miltenyi Biotec
10.9 InVitria
10.10 PeproTech
10.11 Wuhan Healthgen Biotechnology
Chapter 11. Research Methodology
11.1 Research Approach
11.2 Data Collection & Sources
11.3 Market Estimation & Forecasting
11.4 Data Validation & Triangulation
Chapter 12. Standard Report Commercials & Add-OnsChapter 13. List Of FiguresChapter 14. List Of Tables
Company Listing
Thermo Fisher Scientific
Merck KGaA (MilliporeSigma)
Sartorius AG
Albumedix
Takara Bio
CellGenix
Macopharma
Miltenyi Biotec
InVitria
PeproTech
Wuhan Healthgen Biotechnology
Market Segments
Market Segmentation
By product type: human serum albumin, human platelet lysate, recombinant cytokines, fibronectin fragments, other. By application: CAR-T, NK cell therapy, stem cell therapy, other. By source: recombinant human-derived, plasma-derived. By end-user: biopharmaceutical companies, CDMOs, academic/research.
Frequently asked questions
What drives market growth?
The expanding clinical pipeline, rising CAR-T commercial demand, the shift from fetal bovine serum to human platelet lysate, growth in recombinant cytokines, and the broader cell therapy market.
Which region grows fastest?
Asia Pacific, at a projected 20.1% CAGR.
Which region dominates?
North America, with about 44% share.
What is the projected market size?
About USD 18.94 billion by 2035, at a 16.3% CAGR from 2026 to 2035.
Global Cell Therapy Human Raw Materials Market 2026 – 2035 — sample pages, full table of contents and the list of data tables, by email within one business day.